Humira (Adalimumab) for Psoriasis

Overview
Humira is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe chronic plaque psoriasis and active psoriatic arthritis. Humira may be prescribed alone or in addition to conventional disease-modifying antirheumatic drugs (DMARDs) such as methotrexate. Humira is also known by its drug name, adalimumab.

Humira belongs to a class of medications called biologics. Humira is a tyrosine kinase inhibitor. Humira is a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Humira is believed to work by inhibiting tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks.

How do I take it?
Humira is administered every other week by subcutaneous injection.

Humira is available as a pen or prefilled syringe.

Side effects
The FDA-approved label for Humira lists common side effects including respiratory infections, headache, redness or irritation at injection sites, and rash.

Rare but serious side effects listed for Humira can include severe infections, allergic and hypersensitivity reactions, demyelinating disease, heart failure, lupus-like syndrome, and increased risk for developing certain types of cancer such as lymphoma.

For more details about this treatment, visit:

Humira — AbbVie
https://www.humira.com